Brokers Set Expectations for CGTX FY2024 Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Equities researchers at Brookline Capital Management issued their FY2024 earnings per share (EPS) estimates for Cognition Therapeutics in a research report issued on Monday, January 27th. Brookline Capital Management analyst T. Bussian anticipates that the company will post earnings per share of ($0.83) for the year. Brookline Capital Management currently has a “Strong-Buy” rating on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.86) per share. Brookline Capital Management also issued estimates for Cognition Therapeutics’ Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.15) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($0.95) EPS.

A number of other brokerages have also recently weighed in on CGTX. B. Riley raised shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $1.00 to $1.50 in a research report on Thursday, December 19th. Chardan Capital reissued a “buy” rating and issued a $11.00 target price on shares of Cognition Therapeutics in a research note on Thursday, December 19th. Finally, HC Wainwright upped their price target on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Thursday, December 19th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Cognition Therapeutics has an average rating of “Buy” and an average target price of $8.30.

Cognition Therapeutics Stock Up 1.0 %

CGTX stock opened at $0.77 on Wednesday. The company has a market cap of $31.92 million, a price-to-earnings ratio of -0.79 and a beta of 0.95. The business has a fifty day simple moving average of $0.61 and a 200-day simple moving average of $0.69. Cognition Therapeutics has a 52 week low of $0.34 and a 52 week high of $2.95.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in Cognition Therapeutics during the 4th quarter worth $26,000. Virtu Financial LLC acquired a new stake in shares of Cognition Therapeutics during the third quarter valued at about $27,000. Sigma Planning Corp increased its position in shares of Cognition Therapeutics by 14.6% during the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after acquiring an additional 25,050 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV lifted its stake in shares of Cognition Therapeutics by 33.4% in the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after acquiring an additional 24,050 shares in the last quarter. 43.35% of the stock is currently owned by hedge funds and other institutional investors.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.